Open Access<p>Recombinant Viral Capsid Protein L2 (rVL2) of HPV 16 Suppresses Cell Proliferation and Glucose Metabolism via ITGB7/C/EBPβ Signaling Pathway in Cervical Cancer Cell Lines</p>
Author(s) -
Zhihong Chai,
Yufei Yang,
Zhongyi Gu,
Xianhua Cai,
Wenwei Ye,
Lin Kong,
Xiaoxiao Qiu,
Lingxiao Ying,
Ziliang Wang,
Linyou Wang
Publication year - 2019
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s228631
Subject(s) - glut1 , cell growth , glucose uptake , glycolysis , cancer research , cell culture , carbohydrate metabolism , cell , western blot , signal transduction , capsid , biology , cervical cancer , cancer cell , microbiology and biotechnology , metabolism , chemistry , biochemistry , cancer , virology , virus , endocrinology , gene , insulin , genetics
Capsid protein L2 is the minor capsid protein of human papillomavirus 16 (HPV16). Although L2-based vaccines were developed, the therapeutic effect of recombinant viral capsid protein L2 (rVL2) was still to be illustrated.